At the conclusion of this application-based activity, participants will be able to:
  • Review the molecular pathology of advanced lung cancer and examine its relevance for clinical practice.
  • Appraise the safety and efficacy of first-line therapies for advanced NSCLC, including chemotherapy and 1st and 2nd generation EGFR TKIs.
  • Evaluate treatment approaches used to overcome EGFR resistance in advanced NSCLC, including the safety and efficacy of second- and third-line therapies.
  • Differentiate recommended molecular testing and role for ctDNA in detecting EGFR mutations, including T790M.